Next-generation sequencing-based analysis of prostate tissue microbiome in prostate cancer patients: a hospital-based study.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
OBJECTIVE: The incidence of prostate cancer has increased by 3% annually, between 2014 and 2019, signalling a reversal in the trend of declining rates observed over the prior two decades. A new perspective that includes the microbiome put a light on cancer biology research. Advancements in molecular technologies have made it feasible and accessible to understand the host and microbiome relation. This knowledge remains limited and unclear, especially regarding the Indian population. MATERIALS AND METHOD: A cross-sectional analytical study was carried out on ten patients, among which seven were PCa (Prostate cancer) and three were BPH (Benign Prostatic hyperplasia). Prostate tissue samples were taken from patients advised to undergo a TRUS (Transrectal ultrasound scan) biopsy. Next-generation sequencing was used to determine the genotypic characters of the microbiome present in PCa and BPH patient samples. RESULTS: Our study reported a potential correlation between the presence of specific bacteria and the Gleason score. A noteworthy rise in the abundance of specific bacteria like Bacteroides, F. nucleatum, E. faecalisia, Bifidobacterium adolescentis and Lactobacillus plantarum was observed in BPH and PCa samples. CONCLUSION: The difference between the microbiome and prostate cancer could later be used to improve the treatment for better diagnosis, further avoiding unnecessary over-treatment or inadequate treatment for prostate cancer patients.